A New Jersey appeals court yesterday threw out jury verdicts totaling $83 million in separate pelvic mesh lawsuits against Johnson & Johnson’s (NYSE:JNJ) Ethicon division and Becton Dickinson (NYSE:BDX) subsidiary C.R. Bard. In both cases, Bergen County, N.J. judges erred by disallowing evidence showing that each company’s mesh product had received FDA 510 (k) clearance, according […]
C.R. Bard
Bard prevails in pelvic mesh trial
The Supreme Court of Missouri ruled in favor of Becton Dickinson’s (NYSE:BDX) C.R. Bard business in a lawsuit alleging liability issues with its pelvic mesh. In 2013, Eve Sherrer filed claims over polypropylene mesh slings that she’d had implanted in 2011 and 2012 to treat urinary incontinence, including claims for negligence, design and manufacturing defects, and […]
AdvaMed launches campaign against ‘misleading’ legal advertising
Medtech trade group AdvaMed this week debuted a website that tracks law firm TV advertisements aimed at patients who have had certain medical devices implanted. The “Responsible Advertising for Patient Safety” site says that such ads mislead patients into legal action against the manufacturers of devices that are “non-faulty” and may jeopardize patient safety. Get the full […]
BD is paying $60M to settle Bard pelvic mesh suits with most U.S. states
Becton Dickinson (NYSE:BDX) will pay $60 million to 48 U.S. states to resolve allegations that its C.R. Bard business deceptively marketed transvaginal surgical mesh devices, state attorneys general in California and Washington announced today. Mesh products were meant to treat the weakening of the muscles and ligaments supporting a woman’s pelvic organs, but they instead sparked […]
DTW Podcast: Vizient on PPE, Vicarious on VR-aided robotics and let’s all hope for pumpernickel
This week’s episode of DeviceTalks Weekly is brought to you by the later V, as in Vizient and Vicarious Surgical. Bharat Sundaram, COO and president of Vizient, will share how the healthcare supplier is strengthening the supply of PPE for hospitals. He’ll also reveal when the company expects to see US hospitals running at pre-COVID […]
Federal appeals court rejects preemption argument from BD’s Bard
The 9th U.S. Circuit Court of Appeals has handed down an important medical device preemption opinion as it affirmed a $3.6 million award against Becton Dickinson & Co. (NYSE:BDX) subsidiary C.R. Bard in a bellwether lawsuit case over inferior vena cava filters. Bard’s lawyers had argued that when FDA reclassified intravascular filters as Class II devices, the […]
Report: Ethylene oxide levels high near Georgia medtech sterilization plants
This article has been updated to include comments from Sterigenics. Medical device sterilization plants in the Atlanta area have come under scrutiny from neighbors and state officials following the publication of an investigative report by Georgia Health News and WebMD. Ethylene oxide plants owned by Sterigenics in Atlanta and Becton Dickinson in Covington, Ga., reported […]
BD’s Bard pulls all pelvic mesh products from EU market
Becton Dickinson & Co. (NYSE:BDX) subsidiary C.R. Bard is removing its women’s pelvic organ prolapse and stress urinary incontinence mesh devices from the European Market, according to a recently posted field corrective action from the company. The Murray Hill, N.J.-based company said that it is “initiating a cease in production and distribution of these devices and a […]
Bard wins surgical mesh case on appeal
C.R. Bard (NYSE:BCR) and subsidiary Davol have won their appeal in a lawsuit involving a woman who died a year after having a Bard surgical mesh patch implanted to repair a hernia. The three-judge panel of the U.S. Court of Appeals for the Southern District of Indiana (Seventh Circuit) found that the estate of Georgia […]
QT Vascular expands pivotal trial of Chocolate Touch DCB
QT Vascular said today that the FDA approved the company’s request to expand an on-going pivotal study of its Chocolate Touch drug-coated balloon to include the use of atherectomy for lesion preparation. The U.S. regulatory agency also approved the addition of subgroup analysis related to the use of atherectomy. Get the full story at our sister […]
BD’s Bard updates on higher restenosis rate for LifeStream covered iliac stent
C.R. Bard (NYSE:BCR) has notified buyers of its LifeStream covered iliac stent of a higher-than-anticipated restenosis rate among patients. The field notice issued by Bard, parent company BD and Irish catheter-maker ClearStream Technologies said the restenosis rate of 0.04% exceeds the acceptable failure rate of 0.01%. An unspecified number of restenosis complaints was reported following implantation of […]
